PARP inhibitors can shrink tumors in pancreatic cancer patients with specific mutations

(University of Pennsylvania School of Medicine) Switching pancreatic cancer patients to the PARP inhibitor rucaparib as maintenance therapy may represent new treatment paradigm for pancreatic cancer patients with BRCA mutations.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news